Trial Search Results
Bilirubin Binding Capacity to Assess Bilirubin Load in Preterm Infants
Most preterm newborns are managed by phototherapy to reverse hyperbilirubinemia with the intent to prevent bilirubin neurotoxicity. A threshold-based relationship between a specific total bilirubin level and need for intervention has been elusive. This is most likely due to other biomarkers such as hemolysis, developmental maturation, concurrent illnesses, or even interventions, may impede bilirubin/albumin binding. The over-prescription of phototherapy has impacted clinical and family-centered care, and in the extreme preterm infants, it may have augmented their risk of mortality. Thus, the opportunity to individualize phototherapy in in order to reduce its use is unique. The investigators have assembled a transdisciplinary team to examine critical unanswered questions including the role of bilirubin binding capacity (BBC) of an individual during the first week of life in the context of clinical modifiers and antecedents for a domain of bilirubin-induced neurologic disorders, that includes neuro-anatomical, hearing, visual and developmental processing impairments. In this study, the investigator will evaluate two new innovative nanotechniques to quantify bilirubin load for the first time in the context of a clinical decision algorithm to identify those most at risk for any bilirubin-related neurotoxicity. The investigators anticipate that knowledge gained from this study will lead to ethically testable hypotheses to individualize the prescription of phototherapy.
Stanford is currently accepting patients for this trial.
Collaborator: Smith-Kettlewell Eye Research Institute
- Other: Bilirubin Binding Capacity
- Other: End-tidal Carbon Monoxide
- Other: Carboxyhemoglobin
- Patients (GA 24 to ≤34 wks)
- Major life-threatening anomalies and diagnosed inborn errors of metabolic disorders
- Attending physician or parent refusal
Ages Eligible for Study
24 Weeks - 34 Weeks
Genders Eligible for Study